Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer
Authors:
- Teppei NishiiTNTeppei Nishii
- Tomoyuki YokoseTYTomoyuki Yokose
- Yohei MiyagiYMYohei Miyagi
- Yataro DaigoYDYataro Daigo
- Hiroyuki ItoHIHiroyuki Ito
- Tetsuya IsakaTITetsuya Isaka
- Kentaro ImaiKIKentaro Imai
- Shuji MurakamiSMShuji Murakami
- Tetsuro KondoTKTetsuro Kondo
- Haruhiro SaitoHSHaruhiro Saito
- Fumihiro OshitaFOFumihiro Oshita
- Kouzo YamadaKYKouzo Yamada
Open Access
- 25 August 2014
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-7
Abstract
The rapid aging of the population in Japan has been accompanied by an increased rate of surgery for lung cancer among elderly patients. It is thus an urgent priority to map out a treatment strategy for elderly patients with primary lung cancer. Although surgical resection remains standard treatment for early stage non–small-cell lung cancer (NSCLC), it is now essential to confirm the status of epidermal growth factor receptor (EGFR) gene mutations when planning treatment strategies. Furthermore, several studies have reported that EGFR mutations are an independent prognostic marker in NSCLC. However, the relations between age group and the molecular and pathological characteristics of NSCLC remain unclear. We studied the status of EGFR mutations in elderly patients with NSCLC and examined the relations of EGFR mutations to clinicopathological factors and outcomes according to age group. A total of 388 consecutive patients with NSCLC who underwent complete tumor resection in our hospital from 2006 through 2008 were studied retrospectively. Formalin-fixed, paraffin-embedded tissue sections were used to isolate DNA from carcinoma lesions. Mutational analyses of EGFR gene exons 19, 20, and 21 and KRAS gene exons 12 and 13 were performed by loop-hybrid mobility shift assay, a highly sensitive polymerase chain reaction-based method. EGFR mutations were detected in 185 (47.7%) and KRAS mutations were detected in 33 (8.5%) of the 388 patients. EGFR mutations were found in a significantly higher proportion of patients younger than 80 years (younger group; 178/359, 49.6%) than in patients 80 years or older (older group; 7/29, 24.1%) (P = 0.008). In contrast, KRAS mutations were more common in the older group (6/29, 20.7%) than in the younger group (27/359, 7.5%) (P = 0.014). The older group showed a trend toward a higher rate of 5-year overall survival among elderly patients with EGFR mutations (100%) than among those with wild-type EGFR (66.2%), but the difference was not significant. Our results suggest that the EGFR status of patients with NSCLC differs between patients 80 years or older and those younger than 80 years. EGFR mutation status might be a prognostic marker in elderly patients with completely resected NSCLC.Keywords
This publication has 22 references indexed in Scilit:
- The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung CancersThe Annals of Thoracic Surgery, 2013
- Trends in smoking and lung cancer mortality in Japan, by birth cohort, 1949–2010Bulletin of the World Health Organization, 2013
- Customized chemotherapy based on epidermal growth factor receptormutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trialBMC Cancer, 2012
- Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancerCancer Science, 2007
- Distinctive Evaluation of Nonmucinous and Mucinous Subtypes of Bronchioloalveolar Carcinomas inEGFRand K-rasGene-Mutation Analyses for Japanese Lung AdenocarcinomasAmerican Journal of Clinical Pathology, 2007
- Rapid and Simple Detection of Hot Spot Point Mutations of Epidermal Growth Factor Receptor, BRAF, and NRAS in Cancers Using the Loop-Hybrid Mobility Shift AssayThe Journal of Molecular Diagnostics, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- WHO Framework Convention on Tobacco Control: development of an evidence based global public health treatyBMJ, 2003